Monkeypox

Virax Biolabs Group Limited Announces Initiation of its Virax Immune COVID-19 Analytical Performance Study

Retrieved on: 
Wednesday, October 26, 2022
Disease, Therapy, Pandemic, Growth, Virus, Diagnosis, Director, Immunity, Antibody, Patient, Monkeypox, Research, COVID-19, Technology, Immune system, Company, IVD, Degenerative disease, Board, Intention, Nature, Hepatitis B, Environment, Vaccination, HPV, Forward-looking statement, Terminology, Vaccine, Herpes simplex, Malaria

LONDON, Oct. 26, 2022 /PRNewswire/ -- Virax Biolabs Group Limited ("Virax" or the "Company") (Nasdaq: VRAX), an innovative biotechnology company focused on the detection of immune responses and diagnosis of viral diseases, announced today the initiation of its Virax Immune COVID-19 Analytical Performance Study scheduled to take place through Q4 of this year and finishing in Q1 of next year.

Key Points: 
  • LONDON, Oct. 26, 2022 /PRNewswire/ -- Virax Biolabs Group Limited ("Virax" or the "Company") (Nasdaq: VRAX), an innovative biotechnology company focused on the detection of immune responses and diagnosis of viral diseases, announced today the initiation of its Virax Immune COVID-19 Analytical Performance Study scheduled to take place through Q4 of this year and finishing in Q1 of next year.
  • The Analytical Performance Study will evaluate the technical performance of the Virax Immune COVID-19 Flow Cytometry Kit and will include specimens from 96 healthy volunteers1.
  • The first test being developed using the Virax Immune platform is for immunity related to COVID-19.
  • Founded in 2013, Virax Biolabs is an Innovative Biotechnology company focused on the diagnosis of and the detection of immune responses to viral diseases.

Detection of COVID-19 Viral RNA in Wastewater as a Simple and Sensitive Method of Outbreak Detection in Large Populations, Upcoming Webinar Hosted by Xtalks

Retrieved on: 
Tuesday, October 25, 2022
Salmonella, Workflow, MBS, RNA, Monkeypox, Analytik Jena, PCR, Industry, Incidence, Food, COVID-19, Compliance, Vaccine, Listeria

TORONTO, Oct. 25, 2022 /PRNewswire-PRWeb/ -- During recent months, monitoring COVID-19 viral RNA in wastewater has been proposed as a method of detecting local outbreaks and has been implemented in several municipalities.

Key Points: 
  • In this free webinar, learn about the detection of COVID-19 viral RNA in wastewater as a simple and sensitive method of outbreak detection in large populations.
  • Attendees will gain insights about the significance of wastewater-based epidemiology and wastewater analysis as a tool for early detection of outbreaks.
  • The featured speaker will discuss how to detect and quantify pathogens in wastewater using a fast, simple and scalable workflow.
  • For more information, or to register for this event, visit Detection of COVID-19 Viral RNA in Wastewater as a Simple and Sensitive Method of Outbreak Detection in Large Populations .

BlueDot announces new leadership as it prepares for rapid growth in 2023

Retrieved on: 
Tuesday, October 25, 2022
Infection, CDC, Growth, COVID, Medtech, Roche, COVID 19, Intelligence, Private sector, Air Canada, Veterinary medicine, Publication, Monkeypox, Master, Doctor of Philosophy, Industry, AI, CEO, Leadership, Porter Airlines, Philips, BlueDot, Union Pearson Express, City, Taiwan, COVID-19, List of life sciences, Management, Pharmaceutical industry, Taiwan Centers for Disease Control, Marketing, Epidemiology

TORONTO, Oct. 25, 2022 /PRNewswire-PRWeb/ -- BlueDot Inc., the leading artificial and human intelligence organization for detecting, assessing, and responding to global infectious diseases, announced the expansion of its executive team as it enters its next phase of growth. As part of the company's continued work in building private and public sectors' resiliency to outbreaks, BlueDot announced the hires of Les Lengyel, Vice President of Sales and Jannine Krish, Vice President of Marketing, in addition to the promotion of Dr. Andrea Thomas to Director of Epidemiology.

Key Points: 
  • With over a decade in Philips Healthcare and Roche respectively alone, he brings a critical understanding of how to drive successful key initiatives and company growth.
  • Through a combination of storytelling and performance marketing, she's led marketing strategies that build industry leadership, consumer trust and business results.
  • Dr. Andrea Thomas has been a predominant figure in driving excellence in epidemiology at BlueDot over the past five years.
  • "Our company went through a rapid phase of growth during the height of the COVID 19 pandemic," said Dr. Kamran Khan, Founder and CEO, BlueDot.

Tonix Pharmaceuticals to Present at the 2022 ThinkEquity Conference

Retrieved on: 
Wednesday, October 19, 2022
U.S. Securities and Exchange Commission, Infection, Disease, Long COVID, IR, Therapy, SEC, Government, Conference, CD40L, Degenerative disease, Breakthrough therapy, MDD, Fibromyalgia, Annual report, Lists of diseases, ThinkEquity, Research, Security (finance), Risk, Nasdaq, Orphan drug, Cancer, Monkeypox, Private Securities Litigation Reform Act, Mandarin Oriental Hotel Group, Neurology, SL, Prader–Willi syndrome, Pain, Autoimmunity, CNS, GLOBE, RPV, FDA, COVID-19, Psychiatry, Failure, Central nervous system, Smallpox, Hydrogen chloride, Pharmaceutical industry, Tonix Pharmaceuticals, CD154

CHATHAM, N.J., Oct. 19, 2022 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a clinical-stage biopharmaceutical company, announced today that Jessica Morris, Chief Operating Officer of Tonix Pharmaceuticals, will present at the ThinkEquity Conference on Wednesday, October 26, 2022, at 10:30 a.m.

Key Points: 
  • CHATHAM, N.J., Oct. 19, 2022 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a clinical-stage biopharmaceutical company, announced today that Jessica Morris, Chief Operating Officer of Tonix Pharmaceuticals, will present at the ThinkEquity Conference on Wednesday, October 26, 2022, at 10:30 a.m.
  • Investors interested in arranging a meeting with the Companys management during the conference should contact the ThinkEquity conference coordinator.
  • A webcast of the presentation will be available under the IR Events tab of the Tonix website at www.tonixpharma.com .
  • Tonix initiated a Phase 2 study in Long COVID in the third quarter of 2022 and expects interim data in the first half of 2023.

mergex Confirms Synthesis of a CD8+ T cell Adaptive Vaccine for Smallpox and Monkeypox

Retrieved on: 
Tuesday, October 18, 2022
Monkeypox virus, Smallpox, Zoonosis, Pox, Disease, Fluid mechanics, Virus, Infection, Vaccine, Poxviridae, GMP, Laboratory, Society, Survivor, Severe acute respiratory syndrome coronavirus 2, Intelligence, Monkeypox, Entrepreneurship, Gastroenterology, Severe cognitive impairment, Scar, Construct, World, Kinetics, CEO, World Health Organization, Vaccination, DNA, Peptide, Death, MedRxiv, DG, HLA

The monkeypox virus is part of the same family of double-stranded DNA viruses (Poxviridae) as variola virus, the virus that causes smallpox; they share many highly conserved proteins that make ideal T cell vaccine targets.

Key Points: 
  • The monkeypox virus is part of the same family of double-stranded DNA viruses (Poxviridae) as variola virus, the virus that causes smallpox; they share many highly conserved proteins that make ideal T cell vaccine targets.
  • The fact that the vaccine constructs pathogen peptides come from the eclipse phase of viral replication plays a key role in infection kinetics.
  • Phillip Williams, Chief Scientific Officer at Emergex commented: Were very proud to have synthesized this smallpox and monkeypox vaccine so quickly using intelligence and resources to target highly conserved sequences shared by both viruses.
  • With a fatality rate of >30% in unvaccinated people, there are concerns that smallpox could pose a future biosecurity threat.

BioGX Announces Availability of Xfree PCR Reagents for Monkeypox

Retrieved on: 
Thursday, October 20, 2022
Research, Medical Supplies, Infectious Diseases, Hospitals, Other Health, Health, General Health, Other Science, Science, ISO, Bureau of Oceans and International Environmental and Scientific Affairs, CDC, Water quality, Laboratory, Time, Water, Laboratory developed test, Viral transport media, CGMP, Monkeypox, PixL, PCR, Food safety, Tampa General Hospital, Monkeypox virus, Saline, Central African, TGH, XFree86, National Microbiology Laboratory, Environment, COVID-19, View, Microbiology, Medical device

To address the growing need for simplified, rapid testing for Monkeypox, BioGX, a global provider of easy molecular diagnostic solutions, announced availability of Xfree PCR reagents for Sample-to-Answer Direct Sample PCR on multiple real-time PCR platforms including BioGXs rapid pixl platform.

Key Points: 
  • To address the growing need for simplified, rapid testing for Monkeypox, BioGX, a global provider of easy molecular diagnostic solutions, announced availability of Xfree PCR reagents for Sample-to-Answer Direct Sample PCR on multiple real-time PCR platforms including BioGXs rapid pixl platform.
  • BioGX Monkeypox Xfree PCR reagents validated by TGH leverages the highly successful Xfree extraction-free direct sample testing chemistry that is also included in the BioGX EUA Xfree COVID-19 Direct RT-PCR test, said Robert Martinez, Ph.D., Sr. Director of Scientific Affairs & Strategic Partnerships.
  • He further noted, BioGX Monkeypox reagents incorporate the US CDC primer/probe designs to detect West African and Central African (Congo Basin) clades of the Monkeypox virus, and separately screen for non-variola Orthopox viruses.
  • BioGX is a leading global provider of lyophilized real-time PCR reagents for molecular diagnostics.

Tonix Pharmaceuticals to Participate in the 2022 BIO-Europe Conference

Retrieved on: 
Monday, October 17, 2022
U.S. Securities and Exchange Commission, Infection, Disease, Long COVID, Therapy, SEC, Government, Conference, CD40L, Degenerative disease, Breakthrough therapy, MDD, Fibromyalgia, Annual report, Lists of diseases, Research, Security (finance), Risk, Nasdaq, Orphan drug, Cancer, Monkeypox, Private Securities Litigation Reform Act, Neurology, SL, Prader–Willi syndrome, Pain, Autoimmunity, CNS, GLOBE, Failure, RPV, FDA, COVID-19, Hydrogen chloride, Psychiatry, Central nervous system, Smallpox, Pharmaceutical industry, Tonix Pharmaceuticals, CD154

CHATHAM, N.J., Oct. 17, 2022 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a clinical-stage biopharmaceutical company, announced today that Seth Lederman, M.D., Chief Executive Officer of Tonix Pharmaceuticals, will participate in one-on-one meetings at the 2022 BIO-Europe Conference being held in Leipzig, Germany, October 24-26, 2022.

Key Points: 
  • CHATHAM, N.J., Oct. 17, 2022 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a clinical-stage biopharmaceutical company, announced today that Seth Lederman, M.D., Chief Executive Officer of Tonix Pharmaceuticals, will participate in one-on-one meetings at the 2022 BIO-Europe Conference being held in Leipzig, Germany, October 24-26, 2022.
  • To schedule a meeting with the Companys management at the conference, please submit a meeting request through the BIO-Europe partneringONE system.
  • Tonix is a clinical-stage biopharmaceutical company focused on discovering, licensing, acquiring and developing therapeutics to treat and prevent human disease and alleviate suffering.
  • Tonix initiated a Phase 2 study in Long COVID in the third quarter of 2022 and expects interim data in the first half of 2023.

Bavarian Nordic’s COVID-19 Booster Vaccine Candidate Demonstrates Durable Antibody Response Six Months After Vaccination in Phase 2 Clinical Trial

Retrieved on: 
Monday, October 17, 2022
RNA transfection, Tick-borne encephalitis, Vaccine, Severe acute respiratory syndrome coronavirus 2, Johnson & Johnson, VLP, Licensure, Janssen Pharmaceuticals, Bavarian Nordic, Monkeypox, OMX, Technology, Goal, Immune system, Rabies, COVID-19, CEO, Adult, Safety, Letter, Vaccination, Forward-looking statement, Government, FDA, Pfizer–BioNTech COVID-19 vaccine, Omicron, ExpreS2ion Biotechnologies

COPENHAGEN, Denmark, October 17, 2022 Bavarian Nordic A/S (OMX: BAVA) announced today the results of a six-month follow-up analysis from a Phase 2 clinical trial of ABNCoV2, a VLP-based, non-adjuvanted COVID-19 booster vaccine candidate.

Key Points: 
  • COPENHAGEN, Denmark, October 17, 2022 Bavarian Nordic A/S (OMX: BAVA) announced today the results of a six-month follow-up analysis from a Phase 2 clinical trial of ABNCoV2, a VLP-based, non-adjuvanted COVID-19 booster vaccine candidate.
  • We look forward to generating further data in the ongoing Phase 3 trial that will shortly open sites in Denmark.
  • ABNCoV2 is a next-generation COVID-19 vaccine candidate, initially developed by AdaptVac, Denmark, using their proprietary capsid virus like particle (cVLP) technology.
  • Bavarian Nordic has licensed the global commercialization rights to the vaccine and has assumed the responsibility for further clinical development towards licensure.

Todos Medical CLIA/CAP Lab Provista Submits Emergency Use Authorization Application for MonkeyPox PCR Test to US FDA

Retrieved on: 
Friday, October 14, 2022
Pressure, Method, U.S. Securities and Exchange Commission, TMB-2, Neurodegeneration, US Foods, Biotechnology, LDT, Research, Monocyte, Cancer prevention, Cancer, PCR, EUA, Technology, Knowledge, Infection, Synthase, Immune system, Neuron, Company, Emergency Use Authorization, Legislation, Alzheimer's disease, CEO, GLOBE, Amazon, Brain, Plasma, TBIA, Medicine, Monkeypox, Cell cycle, FDA, Apoptosis, OTCQB, Solution, Lymphocyte, Pharmaceutical industry, Medical imaging, Pharma

The sensitivity achieved for the currently available lesion-based laboratory-developed test (LDT) is 0.95 viral copies per reaction (0.095 copies/ul).

Key Points: 
  • The sensitivity achieved for the currently available lesion-based laboratory-developed test (LDT) is 0.95 viral copies per reaction (0.095 copies/ul).
  • The submission of this EUA application underscores our commitment to providing best-in-class PCR-based testing for emerging infectious diseases, said Gerald E. Commissiong, President & CEO of Todos Medical and Provista.
  • Regulatory changes at FDA have forced us to only be able to offer lesion-based PCR testing.
  • As we conduct more research and work with the agency, we are hopeful to be able to submit an EUA for saliva-based PCR testing for MonkeyPox in the future.

Enzo Biochem Reports Fourth Quarter and Fiscal Year 2022 Financial Results and Provides Business Update

Retrieved on: 
Friday, October 14, 2022
Conference, STI, Hepatitis, FX, Chlamydia, CEO, Operating cost, Public expenditure, DNA, Syphilis, CDC, Biochemistry, New York State Department of Health, Severe acute respiratory syndrome coronavirus 2, DOH, NYSE, Jefferies Group, General counsel, GAAP, Investment, SG, NEW, Center, Company, Industry, Conference call, GLOBE, HPV, FDA, APOE, Growth, Review, COVID-19 testing, Laboratory, Income, EUA, Simplex, Goal, ECL, EBITDA, Internet, Rheumatology, EDX, ENZ, Total, GMP, LDT, Monkeypox, Health, Â, Research, Gonorrhea, ELS, COVID-19, Pharmaceutical industry, Management, Video game, Fine chemical, Vaccine, Reinsurance, Fossil fuel, Enzo, COVID

Enzo Life Sciences fiscal 2022 revenues amounted to $32.6 million, up 6% from fiscal 2021, or 8% on an FX adjusted basis.

Key Points: 
  • Enzo Life Sciences fiscal 2022 revenues amounted to $32.6 million, up 6% from fiscal 2021, or 8% on an FX adjusted basis.
  • Total fourth quarter 2022 revenues were $20.3 million, compared to $24.8 million in the fourth quarter 2021.
  • Consolidated gross margins were 21.4% in the fiscal fourth quarter as compared to 39.5% for the comparable quarter in the previous fiscal year.
  • Enzo Clinical Lab revenue was $12.4 million in the fiscal fourth quarter as compared to $16.8 million in the fourth quarter of 2021.